公开(公告)号：US11419769B2

公开(公告)日：2022-08-23

申请号：US16409257

申请日：2019-05-10

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Nathan John Bryson ,  Anthony John Giovinazzo ,  Scott David Barnhart ,  Michael Clinton Koons

IPC: A61K31/4415 ,  A61K9/00 ,  A61K47/38 ,  A61K31/485 ,  A61P25/16 ,  A61K9/70 ,  A61F13/00 ,  A61K47/02 ,  A61K47/14 ,  A61K31/4045 ,  A61K31/473 ,  A61K45/06 ,  A61K31/381 ,  A61K31/428 ,  A61K31/48 ,  A61K31/4985 ,  A61K31/506 ,  A61J1/03 ,  A61J7/00 ,  B29C39/18 ,  B65D65/38 ,  A61K47/10 ,  A61K47/12 ,  A61K47/22 ,  A61K47/36 ,  B29C39/38 ,  B29C43/30 ,  B29C43/52 ,  B29C65/70 ,  B29C65/00 ,  A61K9/24 ,  B29K1/00 ,  B29L31/00 ,  B29L7/00 ,  B29L9/00

Abstract: The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.

公开(公告)号：US11332462B2

公开(公告)日：2022-05-17

申请号：US16722048

申请日：2019-12-20

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： John Emmerson Campbell ,  Una Campbell ,  Taleen G. Hanania ,  Liming Shao

IPC: C07D409/04 ,  C07D409/14 ,  C07D491/048 ,  C07D495/04 ,  C07D405/04

Abstract: Provided herein are thiophene compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

公开(公告)号：US20220098163A1

公开(公告)日：2022-03-31

申请号：US17347709

申请日：2021-06-15

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Nandkumar Nivritti BHOGLE ,  Takahiko HASHIZUKA ,  Robert Joseph PRYTKO ,  John R. SNOONIAN ,  Harold Scott WILKINSON ,  Haitao ZHANG

IPC: C07D311/76

Abstract: The present disclosure relates to salts of (R)-1-(8-fluoroisochroman-1-yl)-N-methylmethanamine, crystalline forms thereof, and methods of preparation thereof, which are useful in the treatment of CNS disorders.

公开(公告)号：US11160758B2

公开(公告)日：2021-11-02

申请号：US16892641

申请日：2020-06-04

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Takumi Asada ,  Gerald R. Galluppi ,  Seth Cabot Hopkins ,  Megumi Maruyama ,  Siriporn Toongsuwan ,  Yuki Tsushima

IPC: A61K9/20 ,  A61K31/40 ,  A61K47/38 ,  A61P25/18 ,  A61P25/24

Abstract: Provided are modified release compositions in a solid oral dosage form comprising amisulpride in the form of an unequal mixture of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are formulations employing polymorphs of enantiomeric amisulpride.

公开(公告)号：US20210300942A1

公开(公告)日：2021-09-30

申请号：US17179477

申请日：2021-02-19

Applicant: Sunovion Pharmaceuticals Inc. ,  PGI Drug Discovery LLC

Inventor： Milan CHYTIL ,  Sharon ENGEL ,  Taleen G. HANANIA ,  Vadim ALEXANDROV ,  Emer LEAHY

IPC: C07D498/04 ,  C07D231/56 ,  C07D498/20 ,  C07D498/14 ,  C07D498/22

Abstract: Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein Ring B, A1, A2, R6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.

公开(公告)号：US10959943B2

公开(公告)日：2021-03-30

申请号：US16564864

申请日：2019-09-09

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Scott David Barnhart ,  Michael Clinton Koons ,  Madhu Sudan Hariharan ,  Jordan Dubow ,  Thierry Bilbault ,  Anthony John Giovinazzo

IPC: A61K9/00 ,  A61K47/02 ,  A61K31/473 ,  A61K47/14 ,  A61K47/26 ,  A61K47/36 ,  A61K45/06 ,  A61P25/16 ,  A61K47/10 ,  A61K47/18 ,  A61K47/38 ,  A61K9/70

Abstract: Methods and pharmaceutical unit dosage forms for treating Parkinson's disease in a subject (e.g., an “off” episode in a subject having Parkinson's disease) are described. The pharmaceutical unit dosage forms are films having a first portion including particles containing an acid addition salt of apomorphine and a second portion containing a pH neutralizing agent. The pharmaceutical unit dosage forms can be flexible and have toughness greater than 100 g×mm. The methods can involve administering to a subject having Parkinson's disease a therapeutic dose sufficient to produce an apomorphine plasma concentrate of at least 2.64 ng/mL within 45 minutes after the administration. The subject may be identified as having low uptake, medium uptake, or high uptake of apomorphine administered via oral mucosa.

公开(公告)号：US20210053983A1

公开(公告)日：2021-02-25

申请号：US17006101

申请日：2020-08-28

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Andrea BAUER ,  Nandkumar Nivritti BHOGLE ,  Xiaoxia CHEN ,  Shahla JAMZAD ,  Robert Joseph PRYTKO ,  Kostas SARANTEAS ,  Michael Joseph SIZENSKY ,  Harold Scott WILKINSON ,  Haitao ZHANG

IPC: C07D495/04 ,  A61P25/18 ,  A61K9/20 ,  A61K45/06 ,  A61K31/381 ,  A61P25/00

Abstract: Provided are salts of (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine and various of crystal forms thereof, and compositions, medicaments, pharmaceutically acceptable formulations thereof, and methods of making same. In addition, provided are compounds comprising specific particle size distributions of crystalline (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine HCl and methods of making and modulating the particle size distributions.

公开(公告)号：US20200330719A1

公开(公告)日：2020-10-22

申请号：US16390908

申请日：2019-04-22

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Michael SEGAL ,  Nathan ABEL ,  Spencer BROWN ,  Everett CROSLAND ,  Francisco Javier de ANA ARBELOA ,  Thomas GOODIN ,  Joseph GORDON ,  Michael METZ ,  Daniel NELSON ,  Jae Hong PARK ,  Sean SCANLON ,  Janis SKUJINS ,  Jennet TOYJANOVA

IPC: A61M16/14 ,  G01F1/34 ,  G01K13/00 ,  A61M16/00

Abstract: Described herein are devices, systems and methods for monitoring the use of a nebulized medication, such as can be administered using a nebulizer. These can be used for monitoring a patient undergoing treatment for COPD and improve compliance to the recommended therapy. Monitored parameters include flow, humidity and acceleration and provide data as to the quantity and quality of nebulizer use.

公开(公告)号：US10800738B2

公开(公告)日：2020-10-13

申请号：US16749744

申请日：2020-01-22

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： John R. Snoonian ,  Harold Scott Wilkinson ,  Haitao Zhang

IPC: C07D207/09

Abstract: The various aspects present inventions provide various crystalline forms of (S)-(−)-amisulpride, (R)-(+)-amisulpride, and solvates thereof and methods of making same. In various aspects, the inventions also provide methods of resolving racemic amisulpride.

公开(公告)号：US10576058B2

公开(公告)日：2020-03-03

申请号：US16452880

申请日：2019-06-26

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Seth Cabot Hopkins ,  Kenneth Stephen Koblan ,  John R. Snoonian ,  Harold Scott Wilkinson

IPC: A61K31/40 ,  A61P25/24

Abstract: Provided are compositions comprising unequal mixtures of (R)-amisulpride and (S)-amisulpride, or pharmaceutically acceptable salts thereof, where the amount of (R)-amisulpride is greater than the amount of (S)-amisulpride, compositions and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens. In addition, provided are various formulations thereof, including, but not limited to, formulations employing polymorphs of enantiomeric amisulpride.